Mesoblast Limited (MESO) Receiving Somewhat Favorable News Coverage, Study Finds
Media coverage about Mesoblast Limited (NASDAQ:MESO) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mesoblast Limited earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.282965402899 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Future Market Trends of Middle East and Africa Stem Cell Market. (reports.pr-inside.com)
- ETFs with exposure to Mesoblast Ltd. : October 23, 2017 (finance.yahoo.com)
- Middle East and Africa Regenerative Medicines Market Growth – Market Data Forecast (reports.pr-inside.com)
- Critical Analysis: Chromadex Corp (CDXC) vs. Mesoblast Limited (MESO) (americanbankingnews.com)
- Mesoblast Limited – American De (NASDAQ:MESO) Sees Light Trading Volume with 585 Shares Changing Hands – First News 24 (firstnewspaper24.com)
Several brokerages recently issued reports on MESO. Zacks Investment Research upgraded shares of Mesoblast Limited from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research report on Wednesday, October 4th. Credit Suisse Group set a $11.00 price target on shares of Mesoblast Limited and gave the stock a “hold” rating in a research report on Tuesday, July 18th. Cantor Fitzgerald set a $20.00 price target on shares of Mesoblast Limited and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Maxim Group set a $14.00 price target on shares of Mesoblast Limited and gave the stock a “buy” rating in a research report on Wednesday, August 30th. Finally, CIBC began coverage on shares of Mesoblast Limited in a research report on Thursday, August 31st. They set an “outperform” rating and a $16.00 price target on the stock. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Mesoblast Limited has an average rating of “Hold” and a consensus price target of $13.14.
Shares of Mesoblast Limited (NASDAQ MESO) traded down 6.02% on Tuesday, reaching $6.24. 27,878 shares of the company traded hands. Mesoblast Limited has a one year low of $4.01 and a one year high of $12.50. The company’s market capitalization is $530.05 million. The firm’s 50 day moving average is $6.06 and its 200 day moving average is $7.81.
COPYRIGHT VIOLATION NOTICE: “Mesoblast Limited (MESO) Receiving Somewhat Favorable News Coverage, Study Finds” was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/mesoblast-limited-meso-receiving-somewhat-favorable-news-coverage-study-finds/1652211.html.
About Mesoblast Limited
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.